Janux Therapeutics, Inc. vs KalVista Pharmaceuticals, Inc. — Valuation Comparison 2026
Access all valuation models for JANX vs KALV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →KALV scores higher with a 6.3/10 quality rating vs JANX's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Janux Therapeutics, Inc. (JANX) and KalVista Pharmaceuticals, Inc. (KALV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
JANX currently trades at $14.74 with a QOC of 5.4/10, while KALV trades at $26.77 with a QOC of 6.3/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).